AI assistant
CLEVER CULTURE SYSTEMS LIMITED — Call Transcript 2018
May 6, 2018
64614_rns_2018-05-06_5c87455c-8979-479c-8654-215bea221aa0.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [172 x 44] intentionally omitted <==
QUARTERLY INVESTOR CALL DETAILS
8.30am AEST, Thursday 10 May 2018 to discuss Results and Business Outlook
Adelaide, Australia, 7 May 2018: LBT Innovations Limited (ASX: LBT) ( LBT or the Company ), a leader in medical technology automation using artificial intelligence, announces that the Company will hold an investor call at 8.30am AEST (8.00am Adelaide time) on Thursday, 10 May 2018 , hosted by CEO, Mr Brent Barnes, to discuss the operational and financial results for the Quarter ended 31 March 2018 and the outlook for the business.
Investor Conference Call details
To dial into the call directly, please dial in 5 to 10 minutes prior to the call time and enter the Conference ID: 803 588 Dial in numbers are as follows:
Australian Toll Free: 1 800 908 299 New Zealand callers 0800 452 795 Other callers: +61 2 9007 8048
To pre-register for the call, please follow the link below. A unique pin number will be provided for use when dialling into the call, which will bypass the operator and provide immediate access to the event.
https://services.choruscall.com.au/diamondpass/lbt-803588-invite.html
Accessing the Call after the event
A recording of the call will be available on the Investors section of the Company’s website for 60 days after the call.
– ENDS –
About LBT Innovations
LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and Automated Plate Assessment System (APAS[®] ). Based on LBT’s intelligent imaging and interpretative software, US FDA-cleared APAS[®] automates imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH to commercialise APAS[®] products. LBT’s third product WoundVue[®] is in early development; this is a proposed automated solution to assist in the management of chronic wounds.
CONTACTS
| LBT Innovations | Investor Enquiries | Media Relations |
|---|---|---|
| Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E:[email protected] |
David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E:[email protected] |
Sarah Kemter Monsoon Communications Tel: +61 3 9620 3333 E:[email protected] |
Page 1 of 1